-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biogen and MedRhythms recently announced that they have entered into a research and development collaboration to jointly develop MedRhythms' investigational prescription digital therapy MR-004 for the treatment of gait disorder in patients with multiple sclerosis (M.
Under the agreement, Biogen will pay an upfront payment of $3 million, while MedRhythms will be eligible to receive up to $115 million in potential milestone paymen.
Since the beginning of this year, in addition to Biogen and MedRhythms, a large number of domestic and foreign pharmaceutical companies have already announced that they will coopera.
Involving AstraZeneca, Coherus BioSciences, Heidelberg Pharma, AKSO Biopharmaceutical, Insilico, Bio-Science, BeiGene,e.
But it is worth noting that in the tide of cooperation, many pharmaceutical companies choose to "break u.
As on May 9, Johnson & Johnson announced that it had terminated its cooperation and licensing agreement with Bavarian Nord.
The main content of the agreement is to use Bavarian Nordic's MVA-BN technology to develop potential vaccines against hepatitis B virus and human papilloma vir.
It is worth mentioning that Xian Janssen, a subsidiary of Johnson & Johnson, also announced the termination of cooperation with Theravance Biopharma in San Francisco at the end of 202 It is understood that in 2018, Xi'an Janssen and Theravance reached a collaboration with izencitinib, an oral, intestinal-selective JAK inhibitor designed to treat ulcerative colitis and Crohn's disea.
To that end, Xi'an Janssen paid Theravance up to $100 million up front and committed an additional $900 million for potential milestone paymen.
But with the failure of two studies of izencitinib, Johnson & Johnson finally made the decision to terminate the cooperati.
In addition to Johnson & Johnson, on January 4, Junshi Bio released its voluntary announcement of terminating the promotion cooperation agreement with AstraZeneca Pharmaceutica.
The announcement stated that as the commercialization team built by Junshi Bio gradually matured, more indications of its PD-1 product toripalimab injection were successfully included in the new version of the National Medical Insurance List, and the original cooperation agreement was terminated after the two parties negotiat.
In addition, Sanofi also announced at the beginning of the year that it would terminate the cooperation transaction with Sangamo, abandon personalized cell therapy, and shift the research and development focus to allogeneic universal genomic medicine metho.
It is reported that the termination of the cooperation transaction between the two parties will officially take effect on June 28, 2022, and Sanofi will return full control of the sickle cell disease candidate drug SAR445136 to Sanga.
Some analysts believe that the reason for Sanofi's withdrawal from cooperation may be because the sickle cell disease track is becoming increasingly fier.
In general, since 2022, a number of pharmaceutical companies have frequently staged marriage and breakup dramas in the industry, involving local pharmaceutical companies such as Wuzhong Medicine and Betta Pharmaceuticals, as well as multinational companies such as Sanofi and Daiichi Sank.
busine.
The industry believes that at present, many pharmaceutical companies are actively expanding their industrial structure and seeking a variety of cooperation methods to increase their industrial competitiveness; and in this context, whether it is cooperation or separation, it is the choice made by the company for its own profits in the futu.
However, in the future, with the continuous emergence of bio-innovative pharmaceutical companies and the continuous deepening of a series of medical reform policies, the commercial logic of traditional medicine will be unsustainable, and domestic pharmaceutical company cooperation is expected to remain the general tre.
However, whether the cooperation is successful or unsuccessful depends on the market environment and the strategic needs of both parti.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Under the agreement, Biogen will pay an upfront payment of $3 million, while MedRhythms will be eligible to receive up to $115 million in potential milestone paymen.
Since the beginning of this year, in addition to Biogen and MedRhythms, a large number of domestic and foreign pharmaceutical companies have already announced that they will coopera.
Involving AstraZeneca, Coherus BioSciences, Heidelberg Pharma, AKSO Biopharmaceutical, Insilico, Bio-Science, BeiGene,e.
But it is worth noting that in the tide of cooperation, many pharmaceutical companies choose to "break u.
As on May 9, Johnson & Johnson announced that it had terminated its cooperation and licensing agreement with Bavarian Nord.
The main content of the agreement is to use Bavarian Nordic's MVA-BN technology to develop potential vaccines against hepatitis B virus and human papilloma vir.
It is worth mentioning that Xian Janssen, a subsidiary of Johnson & Johnson, also announced the termination of cooperation with Theravance Biopharma in San Francisco at the end of 202 It is understood that in 2018, Xi'an Janssen and Theravance reached a collaboration with izencitinib, an oral, intestinal-selective JAK inhibitor designed to treat ulcerative colitis and Crohn's disea.
To that end, Xi'an Janssen paid Theravance up to $100 million up front and committed an additional $900 million for potential milestone paymen.
But with the failure of two studies of izencitinib, Johnson & Johnson finally made the decision to terminate the cooperati.
In addition to Johnson & Johnson, on January 4, Junshi Bio released its voluntary announcement of terminating the promotion cooperation agreement with AstraZeneca Pharmaceutica.
The announcement stated that as the commercialization team built by Junshi Bio gradually matured, more indications of its PD-1 product toripalimab injection were successfully included in the new version of the National Medical Insurance List, and the original cooperation agreement was terminated after the two parties negotiat.
In addition, Sanofi also announced at the beginning of the year that it would terminate the cooperation transaction with Sangamo, abandon personalized cell therapy, and shift the research and development focus to allogeneic universal genomic medicine metho.
It is reported that the termination of the cooperation transaction between the two parties will officially take effect on June 28, 2022, and Sanofi will return full control of the sickle cell disease candidate drug SAR445136 to Sanga.
Some analysts believe that the reason for Sanofi's withdrawal from cooperation may be because the sickle cell disease track is becoming increasingly fier.
In general, since 2022, a number of pharmaceutical companies have frequently staged marriage and breakup dramas in the industry, involving local pharmaceutical companies such as Wuzhong Medicine and Betta Pharmaceuticals, as well as multinational companies such as Sanofi and Daiichi Sank.
busine.
The industry believes that at present, many pharmaceutical companies are actively expanding their industrial structure and seeking a variety of cooperation methods to increase their industrial competitiveness; and in this context, whether it is cooperation or separation, it is the choice made by the company for its own profits in the futu.
However, in the future, with the continuous emergence of bio-innovative pharmaceutical companies and the continuous deepening of a series of medical reform policies, the commercial logic of traditional medicine will be unsustainable, and domestic pharmaceutical company cooperation is expected to remain the general tre.
However, whether the cooperation is successful or unsuccessful depends on the market environment and the strategic needs of both parti.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
